SAREPTA THERAPEUTICS INC
SRPTNASDAQTrading Snapshot
- Day Range
- $13.26 β $14.47
- 52-Week Range
- $13.25 β $24.68
- Volume (shares)
- 2,253,865
- Avg Volume (shares)
- β
- Shares Outstanding
- 105.6M
- Next Earnings
- 2027-02-23
Fundamentals Snapshot
- Annual Revenue
- $2.20B
- Last Q Revenue
- $381M
- P/E Ratio
- 96.8
- P/S Ratio
- 0.7x
- EPS (TTM)
- $-0.30
- Dividend Yield
- β
- Dilution (1yr)
- β3.4%
SAREPTA THERAPEUTICS INC
SRPTAbout SAREPTA THERAPEUTICS INC
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

Buy, Sell, or Hold? Tuesdayβs Top Upgrades and Downgrades: Cloudflare, Deckers Outdoors, DraftKings, MongoDB, Nike, Oneok, Philip Morris International, Riot Platforms, Wix.com, and More
A two-day rally built partly on short covering faces its first real test when October inflation data lands at 8:30 ET. Meanwhile, analysts flipped hard on Wix and DraftKings, while a surprise double upgrade lifted a bitc

Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs Advance
Sarepta Therapeutics NASDAQ: SRPT expects updates from its experimental neuromuscular disease programs to help shape its next phase of growth, while relying on its Duchenne muscular dystrophy business to fund development

Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call Transcript
Sarepta Therapeutics, Inc. ( SRPT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO & Director Patrick M

SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales Decline
Sarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.

Sarepta Therapeutics Q3 Earnings Call Highlights
Sarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-

Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to W